Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors

July 31, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search